Evidence map›Paper›PMID 38181438›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2024

Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT.

Sabashini K Ramchand, Rudolf Hoermann, Shane White, Belinda Yeo, Prudence A Francis, Cecilia L H Xu, Jeffrey D Zajac, Ego Seeman, Mathis Grossmann

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. From Bone Health to Lifespan: Pleiotropic Effects of Antiresorptive Agents.Endocrinology and metabolism (Seoul, Korea) · 2025
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Sabashini K RamchandDepartment of Medicine, Austin Health, University of Melbourne, Victoria 3084, Australia.ORCID 0000-0002-6755-8469
Rudolf HoermannDepartment of Medicine, Austin Health, University of Melbourne, Victoria 3084, Australia.
Shane WhiteDepartment of Medicine, Austin Health, University of Melbourne, Victoria 3084, Australia.
Belinda YeoDepartment of Medicine, Austin Health, University of Melbourne, Victoria 3084, Australia.
Prudence A FrancisPeter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria 3052, Australia.
Cecilia L H XuDepartment of Medicine, Austin Health, University of Melbourne, Victoria 3084, Australia.
Jeffrey D ZajacDepartment of Medicine, Austin Health, University of Melbourne, Victoria 3084, Australia.
Ego SeemanDepartment of Medicine, Austin Health, University of Melbourne, Victoria 3084, Australia.
Mathis GrossmannDepartment of Medicine, Austin Health, University of Melbourne, Victoria 3084, Australia.ORCID 0000-0001-8261-3457
The University of Melbourne · AUHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextMenopause is associated with changes in musculoskeletal, body composition, and metabolic parameters that may be amplified in premenopausal women receiving estradiol suppression for breast cancer. Denosumab offsets deleterious skeletal effects of estradiol suppression and has been reported to have effects on body composition and metabolic parameters in preclinical and observational studies, but evidence from double-blind randomized controlled trials is limited.

objectiveTo assess the effect of denosumab on body composition and metabolic parameters.

methodsIn a prespecified secondary analysis of a 12-month randomized, double-blind, placebo-controlled trial, 68 premenopausal women with breast cancer initiating ovarian function suppression and aromatase inhibition were randomized to denosumab 60-mg or placebo administered at baseline and 6 months. Outcome measures were total and regional fat and lean mass (DXA), body mass index (BMI), waist and hip circumference, fasting glucose, HOMA-IR, and lipid profile. Using a mixed model, between-group mean adjusted differences over time are reported.

resultsOver 12 months, relative to placebo, android and gynoid fat mass decreased in the denosumab group (-266 g [95% CI -453 to -79], P = .02, and -452 g [-783 to -122], P = .03, respectively). Total fat mass and waist circumference were lower in the denosumab group but not significantly (-1792 g [-3346 to -240], P = .08 and (- 3.77 cm [-6.76 to -0.79], P = .06, respectively). No significant treatment effects were detected in lean mass, BMI, hip circumference, fasting glucose, HOMA-IR, or lipid profile.

conclusionIn premenopausal women receiving estradiol suppression, denosumab decreases some measures of fat mass with no detectable effects on other measures of body composition or metabolic parameters.

Indexed as

Body CompositionBreast NeoplasmsDenosumabEstradiolPremenopauseAdultAromatase InhibitorsBody Mass IndexBone Density Conservation AgentsDouble-Blind MethodFemaleHumansMiddle AgedAromatase InhibitorsBone Density Conservation AgentsDenosumabEstradiolbody compositionbreast cancerdenosumabestradiol suppressionglucose metabolismlipids

Identifiers

PMID38181438
PMCPMC11403315
OpenAlexW4390645713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.